Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension

Hypertension Research

Volumn 31, Issue 2, 2008, Pages 353-361

  Nakamoto, Minori ^a   Ohya, Yusuke ^a   Shinzato, Tomoko ^a   Mano, Rieko ^a   Yamazato, Masanobu ^a   Sakima, Atsushi ^a   Takishita, Shuichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cardiac fibrosis; Peroxisome proliferator activated receptor ; Renin angiotensin system; Salt sensitive hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; INSULIN; MESSENGER RNA; METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; ZYMOGRAPHY;

ANIMALS; BENZIMIDAZOLES; BLOOD GLUCOSE; FIBROSIS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASES; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SIZE; RATS; RATS, INBRED DAHL; RNA, MESSENGER; SYSTOLE; TETRAZOLES; THIAZOLIDINEDIONES;

EID: 41549106626     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.353     Document Type: Article

References (47)

1. Devereux RB, Wachtell K, Gerdts E, et al: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
2. Gosse P: Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005; 23: S27-S33.
3. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G: Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004; 63: 373-380.
4. Frey N, Katus HA, Olson EN, Hill JA: Hypertrophy of the heart: a new therapeutic target? Circulation 2004; 109: 1580-1589.
5. Rysa J, Leskinen H, Ilves M, Ruskoaho H: Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 2005; 45: 927-933.
6. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S: Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39: 1384-1391.
7. Ahmed MS, Oie E, Vinge LE, et al: Connective tissue growth factor - a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004; 36: 393-404.
8. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB: Myofibroblasts. I. Paracrine cells important in Health and disease. Am J Physiol 1999; 277: C1-C9.
9. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J: Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 44: 1609-1618.
10. Spinale FG: Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530.
11. Sakata Y, Yamamoto K, Mano T, et al: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
12. Yamamoto K, Mano T, Yoshida J, et al: ACE inhibitor and angiotensin II type I receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23: 393-400.
13. Nagata K, Obata K, Xu J, et al: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664.
14. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN: Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-668.
15. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071-8076.
16. Ishibashi M, Egashira K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
17. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S: Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994; 267: H2471-H2482.
18. Mizukami M, Hasegawa H, Kohro T, et al: Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure. J Cardiovasc Pharmacol 2003; 42: S1-S6.
19. Zhao X, White R, Van Huysse J, Leenen FH: Cardiac hypertrophy and cardiac renin-angiotensin system in Dahl rats on high salt intake. J Hypertens 2000; 18: 1319-1326.
20. Yoshida J, Yamamoto K, Mano T, et al: AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43: 686-691.
21. Zhou MS, Adam AG, Jaimes EA, Raij L: In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003; 42: 945-951.
22. Guo P, Nishiyama A, Rahman M, et al: Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 2006; 24: 1097-1104.
23. Wake R, Kim-Mitsuyama S, Izumi Y, et al: Beneficial effect of candesartan on rat diastolic heart failure. J Pharmacol Sci 2005; 98: 37237-37239.
24. Wu L, Wang R, De Champlain J, Wilson TW: Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 2004; 17: 749-756.
25. Wakino S, Hayashi K, Tatematsu S, et al: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-262.
26. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL: Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Atheroscler Thromb Vasc Biol 2003; 23: 45-51.
27. Iglarz M, Touyz RM, Viel EC, et al: Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42: 737-743.
28. Benkirane K, Viel EC, Amiri F, Schiffrin EL: Peroxisome proliferator-activated receptor γ regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006; 47: 102-108.
29. Majithiya JB, Parmar AN, Trivedi CJ, Balaraman R: Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. Vascul Pharmacol 2005; 43: 260-266.
30. Yosefy C, Magen E, Kiselevich A, et al: Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215-222.
31. Derosa G, Cicero AFG, D'Angelo A: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924.
32. Ogihara T, Asano T, Ando K, et al: High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension 2002; 40: 83-89.
33. Landsberg L: Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Clin Exp Hypertens 1996; 18: 337-346.
34. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD: PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43: 661-666.
35. Ishimitsu T, Kobayashi T, Honda T, et al: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 2005; 28: 351-359.
36. Yu HC, Burrell LM, Black MJ, et al: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621-2628.
37. Cucoranu I, Clempus R, Dikalova A, et al: NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97: 900-907.
38. Chen K, Chen J, Li D, Zhang X, Mehta JL: Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-γ ligand pioglitazone. Hypertension 2004; 44: 655-661.
39. Sugawara A, Takeuchi K, Uruno A, et al: Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-3134.
40. Takeda K, Ichiki T, Tokunou T, et al: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-1839.
41. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL: PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 2006; 290: H390-H397.
42. Poornima IG, Parikh P, Shannon RP: Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006; 98: 596-605.
43. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005; 97: 372-379.
44. Asakawa M, Takano H, Nagai T, et al: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-1246.
45. Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I: Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 2002; 103 (Suppl 48): 16S-20S.
46. Guan Y, Hao C, Cha DR, et al: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866.
47. Nesto RW, Bell D, Bonow RO, et al, American Heart Association, American Diabetes Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.